ClinicalTrials.gg

Program

seltorexant

Also written as “JNJ-42847922”, “Seltorexant” and “JNJ-42847922, 5 mg”.

Its studies are mostly in Depressive Disorder, Major · Sleep Initiation and Maintenance Disorders · Alzheimer Disease · Sleep Apnea, Obstructive · Renal Insufficiency, led by Johnson & Johnson.

Furthest: phase 3, since Aug 13, 202033 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson332 open or runningphase 3since Aug 13, 2020Jan 22, 2014Dec 30, 2026phase 3 · NCT06559306
  • Named in Johnson & Johnson’s own pipeline as seltorexant, phase 3, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Jan 22, 2014.

  1. Feb 8, 2018Phase 1 study in HealthyNCT03438461 · 49 enrolled · United States
  2. Apr 5, 2018Phase 1 study in HealthyNCT03494907 · 52 enrolled · Belgium
  3. Sep 21, 2018Phase 1 study in HealthyNCT03682380 · 151 enrolled · United States
  4. Jan 4, 2019Phase 1 study in Sleep Apnea, ObstructiveNCT03796026 · 34 enrolled · United States
  5. Jun 26, 2020Phase 1 study in Depressive Disorder, MajorNCT04451187 · 63 enrolled · Belgium, Germany
  6. Aug 13, 20203 phase 3 studies in Depressive Disorder, MajorNCT04513912, NCT04533529, NCT04532749
  7. Sep 14, 2020Phase 1 study in HealthyNCT04553042 · 69 enrolled · United States
  8. Nov 2, 2020Phase 1 study in Renal InsufficiencyNCT04616677 · 24 enrolled · United States
  9. Jun 30, 2021Phase 1 study in Depressive Disorder, MajorNCT04951609 · 31 enrolled · United States, Italy, Spain and more
  10. Jul 2, 2021Phase 1 study in HealthyNCT04960124 · 24 enrolled · Germany
  11. Feb 2, 2022Phase 1 study in HealthyNCT05236868 · 10 enrolled · Netherlands
  12. Mar 25, 2022Phase 2 study in Alzheimer DiseaseNCT05307692 · 88 enrolled · United States
  13. Aug 15, 2024Phase 3 study in Depressive Disorder, MajorNCT06559306 · 752 planned · United States, Argentina, Brazil and more
  14. May 1, 2026Phase 3 study in Depressive Disorder, MajorNCT07573176 · 600 planned · United States, Argentina, Brazil and more

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Depressive Disorder, MajorNCT06559306
  2. Aug 24, 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT07573176

TargetBeta

HCRTR2 →read by rule
“Orexin receptor 2 antagonist”ChEMBL 37, by rule

Other programs on HCRTR2

ProgramCompanyFurthest phaseStudies
daridorexantruleIdorsia Pharmaceuticalsphase 434
HS-10506Hansoh Pharmaceutical Groupphase 36

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07573176Depressive Disorder, Major · United States, Argentina, Brazil and more3RecruitingAug 24, 2028600
NCT06559306Depressive Disorder, Major · United States, Argentina, Brazil and more3RecruitingDec 30, 2026752
NCT05307692Alzheimer Disease · United States2CompletedNov 10, 202388
NCT05236868Healthy · Netherlands1CompletedMar 1, 202210
NCT04960124Healthy · Germany1CompletedNov 19, 202124
NCT04951609Depressive Disorder, Major · United States, Italy, Spain and more1TerminatedApr 8, 202431
NCT04616677Renal Insufficiency · United States1CompletedOct 18, 202224
NCT04553042Healthy · United States1CompletedDec 20, 202069
NCT04532749Depressive Disorder, Major · United States, Argentina, Chile and more3TerminatedMay 24, 2022212
NCT04533529Depressive Disorder, Major · United States, Brazil, Bulgaria and more3CompletedApr 25, 2023588
NCT04513912Depressive Disorder, Major · United States, Argentina, Belgium and more3CompletedOct 3, 2023757
NCT04451187Depressive Disorder, Major · Belgium, Germany1CompletedMar 16, 202363
NCT03796026Sleep Apnea, Obstructive · United States1CompletedJun 7, 201934
NCT03682380Healthy · United States1CompletedAug 23, 2019151
NCT03494907Healthy · Belgium1CompletedAug 13, 201852
NCT03438461Healthy · United States1CompletedMay 30, 201849
NCT03374475Depressive Disorder, Major · United States, Belgium, Germany and more1CompletedApr 29, 2019140
NCT03375203Sleep Initiation and Maintenance Disorders · United States, Belgium, France and more2CompletedApr 3, 2019365
NCT03321526Depressive Disorder, Major · United States2CompletedJun 13, 2019107
NCT03249402Healthy · Belgium1CompletedNov 24, 201724
NCT03227224Depressive Disorder, Major · United States, Bulgaria, Finland and more2CompletedJan 12, 2019287
NCT03025022Healthy · United States1CompletedFeb 27, 20178
NCT02837692Healthy · United States1CompletedSep 7, 2017140
NCT02661893Healthy · United States1CompletedFeb 201614
NCT02617810Healthy · United States1CompletedFeb 201618
NCT02578472Healthy · Netherlands1CompletedFeb 201636
NCT02555124Healthy · Japan1CompletedOct 31, 201524
NCT02475161Healthy · United States1CompletedJul 201516
NCT02464046Sleep Initiation and Maintenance Disorders · United States, Germany, Netherlands2CompletedDec 2, 201528
NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands1CompletedJan 4, 201648
NCT02455856Healthy · Germany1CompletedJun 19, 201516
NCT02230878Healthy · Germany1CompletedNov 201440
NCT02067299Depressive Disorder, Major · Germany, Netherlands1CompletedDec 201420

How it is read

Names in the registry

  • “JNJ-42847922”, 13 entries
  • “Seltorexant”, 10 entries
  • “JNJ-42847922, 5 mg”, 2 entries
  • “JNJ-42847922, 20 mg”, 2 entries
  • “Seltorexant 40 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.